Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5725662 | 0.88 | PPARA (0.54) | SMN1; SMN2KMT2ALMNANPC1RAB9A | |
| SCHEMBL2172192 | 0.81 | CYP19A1 (0.59) | SMN1; SMN2ALDH1A1KMT2AMEN1CYP19A1 | |
| SCHEMBL10174538 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL5206825 | 0.80 | KMT2A (0.54) | SMN1; SMN2ALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL4076916 | 0.79 | LMNA (0.62) | ALDH1A1KMT2ALMNAMEN1CYP2C9 | |
| SCHEMBL5881050 | 0.79 | ALDH1A1 (0.51) | ALDH1A1KMT2ALMNAMEN1CYP2C9 | |
| SCHEMBL4082494 | 0.79 | ALDH1A1 (0.51) | ALDH1A1KMT2ALMNAMEN1CYP2C9 | |
| SCHEMBL4834417 | 0.79 | LOXL2 (0.54) | ALDH1A1KMT2ALMNAMEN1CYP2C9 | |
| SCHEMBL10422717 | 0.79 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL765936 | 0.77 | PPARA (0.61) | ALDH1A1KMT2AMEN1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11180926-A | — | — | None | — | — | JP | disclosed |
| US-20020165255-A1 | Osteoporosis compounds | CAMERON KIMBERLY O (US) | 2002-11-07 | — | — | US | disclosed |
| US-6376502-B1 | PROSTAGLANDIN AGONISTS ARE USEFUL FOR THE TREATMENT OF BONE DISORDERS INCLUDING OSTEOPOROSIS. | PFIZER INC. | 2002-04-23 | — | — | US | disclosed |
| US-6124314-A | A PROSTAGLANDIN AGONISTS FOR TREATING VERTEBRATE BONE DISORDERS | PFIZER INC. (US) | 2000-09-26 | — | — | US | disclosed |
| JP-H11180926-A | COMPOUND FOR OSTEOPOROSIS | PFIZER INC | 1999-07-06 | — | — | JP | disclosed |
| EP-0911321-A2 | Compounds for the treatment of osteoporosis | PFIZER INC. (US) | 1999-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165255-A1 | Osteoporosis compounds | PTGER1, PTGIR, PTGER4 | SMN1; SMN2 3703/4885ALDH1A1 2288/4885KMT2A 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.